Navigation Links
Thesan Pharmaceuticals udpeger Dr. Bhaskar Chaudhuri til bestyrelsen i august 2014
Date:8/25/2014

SAN DIEGO, 25. august 2014 /PRNewswire/ -- Thesan Pharmaceuticals meddelte i dag, at firmaet udpeger Bhaskar Chaudhuri Ph.D. til bestyrelsen. Dr. Chaudhuri har mere end 25 års erfaring i ledelse inden for lægemidler, medicinsk forskning og udvikling og markedsføring i USA, EU og nye markeder. Han har ledet udviklingen og FDA-godkendelsen af flere NDA'er og ANDA'er. Senest var Dr. Chaudhuri adm. direktør for Valeant Phamaceutikals, før han blev arbejdende partner i Frazier Healthcare. Før Dr. Chaudhuri kom til Valeant var han adm. direktør for Dow Pharmaceuticals i perioden op til dette firmas opkøb af Valeant. Før Dow arbejdede Dr. Chaudhuri hos Bertek Pharmaceuticals (et datterselskab af Mylan Laboratories) som viceadm. direktør for videnskab og som direktør for dermatologiafdelingen hos Mylan Laboratories. Dr. Chaudhuri har et doktorat i fysisk farmakopé. Har er også medlem af bestyrelsen for flere lægemiddelselskaber.

"Vi er glade for at få Bhaskar i bestyrelsen på nuværende tidspunkt", sagde Gordon Foulkes, Thesan's adm. direktør. "Hans fantastiske CV inden for udvikling af dermatologimidler, hans markedsføringsekspertise og lederrolle i salget af flere dermatologiselskaber vil blive en fantastisk hjælp hos Thesan, når vi starter på at bygge et lederteam op for fremtiden".

"Jeg er helt klart beæret over at blive et medlem af Thesan-teamet", tilføjede Dr. Chaudhuri. Den aktuelle portefølje af banebrydende produkter, der ledes af et team af verdensklasse, giver Thesan grundlag for at være et ekstraordinært dermatologiselskab. Jeg ser frem til at bidrage til Thesans vækst og blive en del af en førende dermatologiorganisation".

Samtidig og i forbindelse med den nylige Serie B-finansiering vil Dr. Peter Moldt fra Novo Ventures blive det nye Novo-bestyrelsesmedlem, som repræsentant for dette firmas investering i Thesan. Dr. Moldt har masser af erfaring inden for bioteknologi og har været enten adm. direktør, produktionsdirektør eller udviklingschef i en række succesfulde selskaber, herunder Curalogic A/S, som han grundlagde og senere bragte på børsen i 2006. Dr. Moldt kom til Novo Ventures i 2009.

Om Thesan Pharmaceuticals, Inc.

Thesan er et bioteknologisk selskab, der fokuserer på udviklingen og markedsføringen af ny medicin til behandling af dermatologiske lidelser.
Flere oplysninger kan fås på: www.thesanpharma.com

Kontakt:
J. Gordon Foulkes, Ph.D.
Administrerende direktør
Thesan Pharmaceuticals, Inc.
Info@ThesanPharma.com


'/>"/>
SOURCE Thesan Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing
2. Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody
3. RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2014
4. Global Medical Imaging Reagents (Nanoparticles, Fluorescent Proteins, Fluorescent Dyes and Probes, Radiopharmaceuticals and Quantum Dots) Market - Forecast to 2019
5. Oramed Pharmaceuticals Reports Last Patient Out in Phase IIa Trial for ORMD-0801 in Type 1 Diabetes
6. OncoGenex Pharmaceuticals Announces Appointment of John A. Bencich as Vice President and Chief Financial Officer
7. RXi Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell
8. RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars
9. Galmed Pharmaceuticals Reports First Half 2014 Financial Results
10. SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services
11. Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... ... January 11, 2017 , ... As a ... Peru studying the pathogens that cause malaria and tuberculosis. Seeing firsthand the ravages ... discovery. , Now, as an assistant professor of biology and biotechnology at Worcester ...
(Date:1/11/2017)... Ca (PRWEB) , ... January 11, 2017 , ... ... U.S. each year and costing healthcare systems more than $23.7 billion, healthcare ... controlling costs. , Among the most common sepsis-causing pathogens are bacteria and ...
(Date:1/11/2017)... ... January 11, 2017 , ... IsoPlexis ... response analysis platform to measure the proteomic function of individual cells in patients, ... Research (SBIR) grant from the National Institute on Aging of the National Institutes ...
(Date:1/11/2017)... ... , ... Back pain relief technology is now available without a prescription at ... pain relief for WAR members. , This spinal restoration platform boasts utilization of technology ... millions suffering from chronic back pain. , What A Relief Back Pain ...
Breaking Biology Technology:
(Date:12/8/2016)... 8, 2016  Singulex, Inc., the leader in Next ... into a license and supply agreement with Thermo Fisher ... provides Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), ... is used to diagnose systemic bacterial infection and sepsis ... to aid in assessing the risk of critically ill ...
(Date:12/7/2016)... 7, 2016   Veridium , a leader ... of new CEO James Stickland . Stickland, ... of experience, has served in senior executive roles ... specialized in expanding a pipeline of venture capital ... most recently served as managing director of U.K.-based ...
(Date:12/5/2016)... WASHINGTON , Dec. 5, 2016  The ... (NIJ), today published "Can CT Scans Enhance or ... examines the potential of supporting or replacing forensic ... a CT scan. In response to ... NIJ is exploring using CT scans as a ...
Breaking Biology News(10 mins):